These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 26647729

  • 1. CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas.
    Nakayama K, Rahman MT, Rahman M, Nakamura K, Ishikawa M, Katagiri H, Sato E, Ishibashi T, Iida K, Ishikawa N, Kyo S.
    Int J Oncol; 2016 Feb; 48(2):506-16. PubMed ID: 26647729
    [Abstract] [Full Text] [Related]

  • 2. Assessment of HER-2/neu, с-MYC and CCNE1 gene copy number variations and protein expression in endometrial carcinomas.
    Buchynska LG, Brieieva OV, Iurchenko NP.
    Exp Oncol; 2019 Jun; 41(2):138-143. PubMed ID: 31262163
    [Abstract] [Full Text] [Related]

  • 3. Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma.
    Cassia R, Moreno-Bueno G, Rodríguez-Perales S, Hardisson D, Cigudosa JC, Palacios J.
    J Pathol; 2003 Dec; 201(4):589-95. PubMed ID: 14648662
    [Abstract] [Full Text] [Related]

  • 4. Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas.
    Zhang X, Dong Y, Ti H, Zhao J, Wang Y, Li T, Zhang B.
    Hum Pathol; 2013 Nov; 44(11):2571-80. PubMed ID: 24071015
    [Abstract] [Full Text] [Related]

  • 5. Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.
    Noske A, Brandt S, Valtcheva N, Wagner U, Zhong Q, Bellini E, Fink D, Obermann EC, Moch H, Wild PJ.
    Oncotarget; 2017 Feb 28; 8(9):14794-14805. PubMed ID: 27582547
    [Abstract] [Full Text] [Related]

  • 6. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
    Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, Miyazaki K.
    Cancer; 2010 Jun 01; 116(11):2621-34. PubMed ID: 20336784
    [Abstract] [Full Text] [Related]

  • 7. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
    Hussein YR, Weigelt B, Levine DA, Schoolmeester JK, Dao LN, Balzer BL, Liles G, Karlan B, Köbel M, Lee CH, Soslow RA.
    Mod Pathol; 2015 Apr 01; 28(4):505-14. PubMed ID: 25394778
    [Abstract] [Full Text] [Related]

  • 8. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
    Garcia-Dios DA, Lambrechts D, Coenegrachts L, Vandenput I, Capoen A, Webb PM, Ferguson K, ANECS, Akslen LA, Claes B, Vergote I, Moerman P, Van Robays J, Marcickiewicz J, Salvesen HB, Spurdle AB, Amant F.
    Gynecol Oncol; 2013 Feb 01; 128(2):327-34. PubMed ID: 23219661
    [Abstract] [Full Text] [Related]

  • 9. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
    Huvila J, Talve L, Carpén O, Edqvist PH, Pontén F, Grénman S, Auranen A.
    Gynecol Oncol; 2013 Sep 01; 130(3):463-9. PubMed ID: 23777659
    [Abstract] [Full Text] [Related]

  • 10. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
    Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RB, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, Kurman RJ, Levine DA, Wang TL, Shih IeM.
    J Natl Cancer Inst; 2012 Oct 03; 104(19):1503-13. PubMed ID: 22923510
    [Abstract] [Full Text] [Related]

  • 11. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
    Ayhan A, Kuhn E, Wu RC, Ogawa H, Bahadirli-Talbott A, Mao TL, Sugimura H, Shih IM, Wang TL.
    Mod Pathol; 2017 Feb 03; 30(2):297-303. PubMed ID: 27767100
    [Abstract] [Full Text] [Related]

  • 12. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome.
    Nelson GS, Pink A, Lee S, Han G, Morris D, Ogilvie T, Duggan MA, Köbel M.
    Gynecol Oncol; 2013 Nov 03; 131(2):309-14. PubMed ID: 23938375
    [Abstract] [Full Text] [Related]

  • 13. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type.
    Zighelboim I, Goodfellow PJ, Gao F, Gibb RK, Powell MA, Rader JS, Mutch DG.
    J Clin Oncol; 2007 May 20; 25(15):2042-8. PubMed ID: 17513808
    [Abstract] [Full Text] [Related]

  • 14. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
    Konopka B, Janiec-Jankowska A, Kwiatkowska E, Najmoła U, Bidziński M, Olszewski W, Goluda C.
    Hum Pathol; 2011 Nov 20; 42(11):1710-9. PubMed ID: 21531001
    [Abstract] [Full Text] [Related]

  • 15. ESR1 gene amplification in endometrial carcinomas: a clinicopathological analysis.
    Rahman MT, Nakayama K, Rahman M, Ishikawa M, Katagiri H, Katagiri A, Ishibashi T, Sato E, Iida K, Ishikawa N, Nakayama N, Miyazaki K.
    Anticancer Res; 2013 Sep 20; 33(9):3775-81. PubMed ID: 24023309
    [Abstract] [Full Text] [Related]

  • 16. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.
    Nout RA, Bosse T, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, van Eijk R, Ter Haar NT, Smit VT.
    Gynecol Oncol; 2012 Sep 20; 126(3):466-73. PubMed ID: 22609107
    [Abstract] [Full Text] [Related]

  • 17. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
    Noske A, Henricksen LA, LaFleur B, Zimmermann AK, Tubbs A, Singh S, Storz M, Fink D, Moch H.
    Exp Mol Pathol; 2015 Feb 20; 98(1):47-54. PubMed ID: 25527175
    [Abstract] [Full Text] [Related]

  • 18. Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer.
    Rahman M, Nakayama K, Rahman MT, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Miyazaki K.
    Hum Pathol; 2013 Jan 20; 44(1):103-9. PubMed ID: 22939958
    [Abstract] [Full Text] [Related]

  • 19. Differential Expression and Clinical Significance of DNA Methyltransferase 3B (DNMT3B), Phosphatase and Tensin Homolog (PTEN) and Human MutL Homologs 1 (hMLH1) in Endometrial Carcinomas.
    Li W, Wang Y, Fang X, Zhou M, Li Y, Dong Y, Wang R.
    Med Sci Monit; 2017 Feb 21; 23():938-947. PubMed ID: 28220037
    [Abstract] [Full Text] [Related]

  • 20. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma.
    Kuhn E, Bahadirli-Talbott A, Shih IeM.
    Mod Pathol; 2014 Jul 21; 27(7):1014-9. PubMed ID: 24309323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.